<h1 id="cystitis-and-pyelonephritis-in-women">Cystitis and Pyelonephritis in Women</h1>
<p><strong>2010 IDSA and ESMID guidelines on antibiotic selection</strong></p>
<p>Target population = Acute, uncomplicated cystitis and pyelonephritis in women </p>
<ul>
<li>Premenopausal, non-pregnant women without known urological abnormalities or co-morbidities (i.e. DM)</li>
</ul>
<h2 id="acute-uncomplicated-cystitis">Acute uncomplicated cystitis</h2>
<p><strong><span class="drug">Nitrofurantoin</span></strong> (100 mg PO BID x 5 days)
<strong><span class="drug">Trimethoprim</span>-sulfamethoxazole</strong> (1 DS tab PO BID x 3 days)</p>
<ol>
<li>Rising resistance rates </li>
<li>Only give if local antibiogram shows &lt; 20% resistance</li>
</ol>
<p><strong><span class="drug">Fosfomycin</span></strong> (3 gm PO x 1) </p>
<ol>
<li>Slightly less efficiacy compared to standard short-course regimens </li>
</ol>
<p><strong><span class="drug">Pivmecillinam</span></strong> (400 mg PO BID x 3-7 days) </p>
<ol>
<li>Only available in Europe</li>
</ol>
<p><strong><span class="drug">Fluoroquinolones</span></strong> (3-day course of ofloxacin, ciprofloxacin, or levofloxacin) </p>
<ol>
<li>Avoid if possible to minimize selection of drug-resistant organisms</li>
</ol>
<p><strong>Beta-lactams</strong> (3-7 day course of <span class="drug">amoxicillin</span>-clavulanate, <span class="drug">cefdinir</span>, <span class="drug">cefaclor</span>, <span class="drug">cefpodoxime</span>-proxetil) </p>
<ol>
<li>Avoid if possible to minimize selection of drug-resistant organisms</li>
<li> Inferior efficacy compared with standard regimens</li>
<li><span class="drug">Cephalexin</span> less well studied</li>
</ol>
<h2 id="acute-pyelonephritis">Acute Pyelonephritis</h2>
<p><strong>Urine analysis</strong> and <strong>urine culture</strong> should always be performed </p>
<p><strong><span class="drug">Ciprofloxacin</span></strong> (500 mg po BID x 7 days) +/- <strong><span class="drug">ciprofloxacin</span></strong> 400 mg IV x 1 dose
If <strong>&gt; 10% resistance to fluoroquinolones</strong>, give 1-time IV dose:</p>
<ul>
<li><span class="drug">Ceftriaxone</span> 1 gm IV, or </li>
<li>An aminoglycoside </li>
</ul>
<p>If <strong>&lt; 10% resistance rate,</strong> alternative oral fluoroquinolone outpatient dosing options: </p>
<ul>
<li><span class="drug">Ciprofloxacin</span> XR 1000 mg po daily x 7 days, or</li>
<li><span class="drug">Levofloxacin</span> 750 mg po daily x 5 days </li>
</ul>
<p><strong><span class="drug">Trimethoprim</span>-sulfamethoxazole</strong> (1 tab DS PO BID x 14 days) </p>
<ol>
<li>If resistance rate unknown, give 1-time dose of <span class="drug">ceftriaxone</span> 1 gm IV or  aminoglycoside first</li>
</ol>
<p><strong>  Beta-lactams</strong> (10-14 day course) </p>
<ol>
<li>Because of less efficacy, give 1-time dose of <span class="drug">ceftriaxone</span> 1 gm IV or aminoglycoside first </li>
</ol>
<h2 id="references">References</h2>
<ul>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/10589881">Gupta K et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the IDSA and the ESMID. Clin Infect Dis. 2011; 52(5).</a></li>
</ul>
